专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08728793B2 Amphipathic alpha-helical peptide compositions as antiviral agents 有权
标题翻译：两亲性α-螺旋肽组合物作为抗病毒剂
公开(公告)号：US08728793B2
公开(公告)日：2014-05-20
申请号：US12172796
申请日：2008-07-14
申请人： Jeffrey Glenn , Nam-Joon Cho , Curtis W. Frank , Kwang Ho Cheong
发明人： Jeffrey Glenn , Nam-Joon Cho , Curtis W. Frank , Kwang Ho Cheong
IPC分类号： C12N7/04 , C12N7/08 , A61K39/29
CPC分类号： A61K38/162 , A01N37/46 , A61L2/0082 , A61L29/08 , A61L29/16 , A61L31/08 , A61L31/16 , A61L2300/25 , A61L2300/408
摘要： The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
摘要翻译：本发明的特征在于利用两亲性α-螺旋（AH）肽以大小依赖的方式引起含脂质囊泡如包膜病毒破坏的能力的方法和组合物。

2. 发明申请

US20090105151A1 AMPHIPATHIC ALPHA-HELICAL PEPTIDE COMPOSITIONS AS ANTIVIRAL AGENTS 有权
公开(公告)号：US20090105151A1
公开(公告)日：2009-04-23
申请号：US12172796
申请日：2008-07-14
申请人： Jeffrey Glenn , Nam-Joon Cho , Curtis W. Frank , Kwang Ho Cheong
发明人： Jeffrey Glenn , Nam-Joon Cho , Curtis W. Frank , Kwang Ho Cheong
IPC分类号： A61K38/10 , C12N7/00 , A01N1/02
CPC分类号： A61K38/162 , A01N37/46 , A61L2/0082 , A61L29/08 , A61L29/16 , A61L31/08 , A61L31/16 , A61L2300/25 , A61L2300/408
摘要： The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
摘要翻译：本发明的特征在于利用两亲性α-螺旋（AH）肽以大小依赖的方式引起含脂质囊泡如包膜病毒破坏的能力的方法和组合物。

3. 发明申请

US20080125367A1 Agents for treatment of HCV and methods of use 有权
公开(公告)号：US20080125367A1
公开(公告)日：2008-05-29
申请号：US11899393
申请日：2007-09-04
申请人： Jeffrey Glenn , Tina Myers , John Glass
发明人： Jeffrey Glenn , Tina Myers , John Glass
IPC分类号： A61K38/00 , C07K14/00 , A61P43/00 , C07K7/00
CPC分类号： C07K14/005 , A61K38/162 , A61K39/00 , C07K2319/00 , C12N2740/16322 , C12N2770/24222 , G01N33/5767 , G01N2500/02 , G01N2500/10
摘要： An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability of compounds or protocols to disrupt the association of such helices with cytoplasmic membranes permits identification of compounds and protocols which are useful in the treatment of HCV infection. Also useful in the invention are mimics, or function-disrupting ligands, of an amphipathic helix of the nonstructural proteins described herein and antibodies and fragments thereof immunoreactive with said helix.

4. 发明申请

US20060199174A1 Methods and compositions for identifying anti-hcv agents 失效
标题翻译：用于鉴定抗hcv药物的方法和组合物
公开(公告)号：US20060199174A1
公开(公告)日：2006-09-07
申请号：US10528377
申请日：2004-08-18
申请人： Jeffrey Glenn , Shirit Einav , Menashe Elazar
发明人： Jeffrey Glenn , Shirit Einav , Menashe Elazar
IPC分类号： C12Q1/70
CPC分类号： G01N33/5767 , C12Q1/707 , G01N33/56983 , G01N33/6875 , G01N2333/18 , G01N2500/04
摘要： The invention provides methods and compositions for identifying agents for treating infection by viruses that encode a nucleotide-binding NS4B protein, or functional equivalent thereof, e.g., hepatitis C virus (HCV) or other members of the family Flaviviridae. In general, the methods involve contacting an NS4B nucleotide binding motif (NBM)-containing polypeptide with a candidate agent, and determining the effect of the candidate agent on nucleotide binding activity, a nucleotide hydrolyzing activity, or a nucleotide-dependent RNA binding activity of the polypeptide. A candidate agent that inhibits NS4B polypeptide binding to a nucleotide is an anti-viral agent, e.g., an anti-HCV agent. The invention also features a polynucleotide encoding a NS4B polypeptide having a modified NBM (e.g., which is impaired in NTP binding). The subject methods and compositions find use in a variety of therapeutic and screening applications.
摘要翻译：本发明提供用于鉴定用于治疗编码与核苷酸结合的NS4B蛋白或其功能等同物如丙型肝炎病毒（HCV）或黄病毒科的其他成员的病毒感染的药剂的方法和组合物。通常，所述方法包括将含NS4B核苷酸结合基序（NBM）的多肽与候选试剂接触，并确定候选试剂对核苷酸结合活性，核苷酸水解活性或核苷酸依赖性RNA结合活性的影响多肽。抑制NS4B多肽与核苷酸结合的候选试剂是抗病毒剂，例如抗HCV剂。本发明还特征在于编码具有修饰的NBM（例如其在NTP结合中受损的）的NS4B多肽的多核苷酸。主题方法和组合物可用于各种治疗和筛选应用。

5. 发明申请

US20080261906A1 METHODS AND COMPOSITIONS FOR IDENTIFYING ANTI-HCV AGENTS 失效
标题翻译：鉴定抗HCV药物的方法和组合物
公开(公告)号：US20080261906A1
公开(公告)日：2008-10-23
申请号：US11844993
申请日：2007-08-24
申请人： Jeffrey Glenn , Ella Sklan , Kirk Staschke , Tina Myers Oakes
发明人： Jeffrey Glenn , Ella Sklan , Kirk Staschke , Tina Myers Oakes
IPC分类号： A61K31/7052 , C12Q1/70 , A61P31/12
CPC分类号： C07K14/005 , C07K2319/40 , C07K2319/60 , C07K2319/61 , C12N15/1138 , C12N2310/14 , C12N2770/24222 , C12Q1/18 , G01N2333/186
摘要： The invention features methods and compositions for screening for agents that modulate replication of a virus, particularly Flaviviridae virus (particularly hepatitis C virus (HCV)), where the methods provide for detection of agents that modulate the binding of TBC and NS5A, the inhibition of TBC activity, inhibition of Rab1 activity, and/or the expression of the TBC protein and/or Rab1 protein. The invention also features methods of controlling viral replication, and agents useful in such methods.
摘要翻译：本发明的特征在于用于筛选调节病毒，特别是黄病毒科病毒（特别是丙型肝炎病毒（HCV））的复制的试剂的方法和组合物，其中所述方法提供了调节TBC和NS5A的结合的试剂的检测， TBC活性，Rab1活性的抑制和/或TBC蛋白和/或Rab1蛋白的表达。本发明还具有控制病毒复制的方法，以及在这些方法中有用的试剂。

6. 发明授权

US06627610B1 Method for inhibition of viral morphogenesis 失效
标题翻译：抑制病毒形态发生的方法
公开(公告)号：US06627610B1
公开(公告)日：2003-09-30
申请号：US09687267
申请日：2000-10-13
申请人： Jeffrey Glenn
发明人： Jeffrey Glenn
IPC分类号： A61K3800
CPC分类号： C12N7/00 , A61K31/365 , A61K38/005 , C07K14/005 , C12N2760/10122 , C12N2760/10163 , C12Q1/6897 , G01N33/56983 , G01N33/5765 , Y02A50/54
摘要： Viral morphogenesis, production, release or uncoating can be inhibited by effecting inhibition of prenylation of, or inhibition of post-prenylation reactions of, at least one viral protein. The use of inhibitors of prenylation, and post-prenylation reactions, for example, inhibitors of the mevalonate and prenyl group synthesis pathways, inhibitors of prenyl group transferases and mimics of the prenylation target CXXX box are disclosed.
摘要翻译：可以通过抑制至少一种病毒蛋白的异戊二烯化作用或抑制异戊二烯酸化反应来抑制病毒形态发生，产生，释放或释放。公开了使用异戊烯基化和异戊二烯基化反应的抑制剂，例如甲羟戊酸和异戊二烯基合成途径的抑制剂，异戊烯基转移酶的抑制剂和异戊烯基化靶向CXXX盒的模拟物。

7. 发明授权

US07655419B2 Methods and compositions for identifying anti-HCV agents 失效
标题翻译：用于鉴定抗HCV药物的方法和组合物
公开(公告)号：US07655419B2
公开(公告)日：2010-02-02
申请号：US11844993
申请日：2007-08-24
申请人： Jeffrey Glenn , Ella Sklan , Kirk A. Staschke , Tina Myers Oakes
发明人： Jeffrey Glenn , Ella Sklan , Kirk A. Staschke , Tina Myers Oakes
IPC分类号： G01N33/53 , A61K39/29
CPC分类号： C07K14/005 , C07K2319/40 , C07K2319/60 , C07K2319/61 , C12N15/1138 , C12N2310/14 , C12N2770/24222 , C12Q1/18 , G01N2333/186
摘要： The invention features methods and compositions for screening for agents that modulate replication of a virus, particularly Flaviviridae virus (particularly hepatitis C virus (HCV)), where the methods provide for detection of agents that modulate the binding of TBC and NS5A, the inhibition of TBC activity, inhibition of Rab1 activity, and/or the expression of the TBC protein and/or Rab1 protein. The invention also features methods of controlling viral replication, and agents useful in such methods.
摘要翻译：本发明的特征在于用于筛选调节病毒，特别是黄病毒科病毒（特别是丙型肝炎病毒（HCV））的复制的试剂的方法和组合物，其中所述方法提供了调节TBC和NS5A的结合的试剂的检测， TBC活性，Rab1活性的抑制和/或TBC蛋白和/或Rab1蛋白的表达。本发明还具有控制病毒复制的方法，以及在这些方法中有用的试剂。

8. 发明申请

US20060040259A1 Method for inhibition of viral infection 审中-公开
公开(公告)号：US20060040259A1
公开(公告)日：2006-02-23
申请号：US11000691
申请日：2004-11-30
申请人： Jeffrey Glenn
发明人： Jeffrey Glenn
IPC分类号： C12Q1/70 , A61K38/06
CPC分类号： G01N33/502 , A61K31/365 , A61K38/005 , A61K38/06 , C07K14/005 , C12N7/00 , C12N2760/10122 , C12N2760/10163 , C12Q1/18 , C12Q1/6897 , G01N33/5008 , G01N33/5067 , G01N33/56983 , G01N33/5765 , G01N2333/91165 , Y02A50/463 , Y02A50/54
摘要： The invention is directed to inhibiting viral morphogenesis and viral infection. In particular, it concerns effecting such inhibition by inhibiting the prenylation or post prenylation reactions of a viral or host protein.

9. 发明授权

US5503973A Method for inhibition of viral morphogenesis 失效
标题翻译：抑制病毒形态发生的方法
公开(公告)号：US5503973A
公开(公告)日：1996-04-02
申请号：US890754
申请日：1992-05-29
申请人： Jeffrey Glenn
发明人： Jeffrey Glenn
IPC分类号： C12N7/04 , A61K31/365 , A61K38/00 , A61K45/00 , A61P31/12 , C07K14/005 , C07K14/08 , C12N7/06 , C12Q1/02 , C12Q1/18 , C12Q1/68 , G01N33/15 , G01N33/50 , G01N33/569 , G01N33/576 , C12Q1/70 , C12N7/01 , A61K35/76
CPC分类号： G01N33/502 , A61K31/365 , A61K38/005 , C07K14/005 , C12N7/00 , C12Q1/18 , C12Q1/6897 , G01N33/5008 , G01N33/5097 , G01N33/56983 , G01N33/5765 , C12N2770/24222 , C12N2770/24263
摘要： Viral morphogenesis, in particular hepatitis D viral morphogenesis, may be inhibited by effecting inhibition of prenylation of at least one viral protein. The use of inhibitors of prenylation, in particular, inhibitors of the mevalonic synthesis pathway and mimics of the prenylation target CXXX (SEQ ID NO:1) box are disclosed.
摘要翻译：病毒形态发生，特别是丙型肝炎病毒形态发生，可能通过抑制至少一种病毒蛋白的异戊烯基化来抑制。公开了使用异戊烯基化抑制剂，特别是甲羟戊酸合成途径的抑制剂和异戊烯化靶向CXXX（SEQ ID NO：1）盒的模拟物。

10. 发明申请

US20060248606A1 Mouse model for hepatitis C 审中-公开
公开(公告)号：US20060248606A1
公开(公告)日：2006-11-02
申请号：US11480012
申请日：2006-06-29
申请人： Jeffrey Glenn
发明人： Jeffrey Glenn
IPC分类号： A01K67/027 , A61K48/00
CPC分类号： A01K67/027
摘要： A rodent model for HCV infection is obtained by introducing into rodents which harbor a liver-specific defect an expression system which comprises an HCV replicon or a reverse transcript thereof and at least a nucleotide sequence encoding a rescue protein which remedies the defect.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式